^
Association details:
| Biomarker: | EGFR exon 18-25 duplication |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P89.09 - The Landscape of Kinase Domain Duplication (KDD) in Chinese Lung Cancer Patients
Published date:
01/12/2021
Excerpt:
We also observed a 61-year-old male patient benefiting from afatinib, who was diagnosed with T1N3M0 lung adenocarcinoma harboring an EGFR KDD (exon18-25dup). The patient showed partial response (PR) 1 month after afatinib treatment with a progression-free survival (PFS) of 11 months and counting.
